Alnylam Pharmaceuticals Inc
$ 272.67
1.94%
20 Jul - close price
- Market Cap 36,404,875,000 USD
- Current Price $ 272.67
- High / Low $ 275.25 / 266.27
- Stock P/E 67.16
- Book Value 8.06
- EPS 4.06
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.90 %
- 52 Week High 495.55
- 52 Week Low 266.27
About
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$434.83
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 |
| Reported EPS | 1.99 | 1.25 | 2.9 | 0.32 | -0.01 | 0.06 | -0.5 | 0.56 | -0.16 | -0.77 | 1.74 | -1.62 |
| Estimated EPS | 1.47 | 1.5 | 1.75 | 0.15 | -0.37 | -0.14 | -0.39 | -0.69 | -0.63 | -0.77 | -0.96 | -1.34 |
| Surprise | 0.52 | -0.25 | 1.15 | 0.17 | 0.36 | 0.2 | -0.11 | 1.25 | 0.47 | 0 | 2.7 | -0.28 |
| Surprise Percentage | 35.3741% | -16.6667% | 65.7143% | 113.3333% | 97.2973% | 142.8571% | -28.2051% | 181.1594% | 74.6032% | 0% | 281.25% | -20.8955% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.43 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALNY
2026-07-20 20:09:52
This article examines Alnylam Pharmaceuticals (ALNY), Insulet (PODD), and Neurocrine Biosciences (NBIX), three U.S. large-cap health care stocks. It discusses their market positioning, financial outlook, and the balance of opportunities and risks they face amidst current market conditions and upcoming earnings. The analysis highlights their respective strengths and potential challenges, including pipeline progress, market reliance, and legal issues.
2026-07-19 10:39:37
Alnylam Pharmaceuticals (ALNY) recently presented positive Phase 1 and 2 updates for its RNAi candidate mivelsiran, targeting early-onset and Down syndrome-associated Alzheimer’s disease, at AAIC 2026. The company reported long-term biomarker reductions and a favorable safety profile, broadening its neuroscience portfolio. While this progress is encouraging for long-term diversification, investors are also closely watching the pricing dynamics and margin pressures of its TTR franchise, particularly AMVUTTRA.
2026-07-19 10:11:32
Alnylam Pharmaceuticals presented promising Phase 1 and 2 updates on its RNAi candidate mivelsiran for early-onset and Down syndrome-associated Alzheimer’s disease, and other neuroscience programs, at AAIC 2026. The company reported long-term biomarker reductions and a favorable safety profile for mivelsiran, and completed enrollment for its Phase 2 cerebral amyloid angiopathy trial. While these developments support a long-term diversification strategy, Alnylam's near-term focus remains on AMVUTTRA pricing dynamics and potential margin pressures.
2026-07-18 14:11:32
Alnylam Pharmaceuticals (ALNY) stock has fallen to a 52-week low of $273.03, reflecting a 28.79% year-to-date and nearly 13% annual decline amidst biotechnology sector challenges. Despite the downturn, analysts maintain a bullish outlook with price targets up to $550, citing significant upside potential. Recent developments include adjusted price targets from BofA Securities and Truist Securities, and a rally in Alnylam shares following a rival drug's trial failure in the heart disease treatment market, underscoring ongoing analyst interest and market volatility.
2026-07-18 02:39:37
Alnylam Pharmaceuticals is holding its annual virtual meeting on May 20, 2026, where shareholders will vote on the election of three Class I directors, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026. The company reached significant milestones in 2025, including regulatory approvals, strong revenue growth, and achieving profitability. The board emphasizes strong corporate governance, including diversity, regular evaluations, and succession planning.
2026-07-18 02:09:24
Alnylam Pharmaceuticals (ALNY) has initiated a Phase 2 trial for Alzheimer's disease and completed enrollment in a related cerebral amyloid angiopathy study, which could significantly impact its valuation. Despite a recent stock price decline, the company is estimated to be 38.5% undervalued with a narrative fair value of $434.72, though its P/E ratio remains high compared to industry averages. This suggests a potential opportunity for investors if the market corrects towards its intrinsic value, but it also highlights significant valuation risks.
